How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

677 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Polycystic Ovarian Syndrome (Follow-up)

of its recommendations for limiting the use of the highest approved dose (80 mg) of the cholesterol-lowering medication simvastatin (Zocor) because of increased risk of muscle damage. The FDA required changes to the simvastatin label to add new contraindications (should not be used with certain medications) and dose limitations for using simvastatin with certain medications. [ ] Sibutramine On October 8, 2010, Abbott Laboratories and the FDA notified health care professionals and patients about (...) the voluntary withdrawal of the obesity drug sibutramine (Meridia) from the US market because of clinical trial data indicating an increased risk of heart attack and stroke. [ ] Previous Next: Metabolic Derangements In patients with polycystic ovarian syndrome (PCOS) who are obese, endocrine-metabolic parameters markedly improve after 4-12 weeks of dietary restriction. Their sex hormone–binding globulin (SHBG) levels rise, and free testosterone levels fall by 2-fold. [ ] Serum insulin and insulin-like

2014 eMedicine Pediatrics

202. Polycystic Ovarian Syndrome (Overview)

injury. Posted: March 1, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: statin drugs - drug safety communication: class labeling change. Posted: February 28, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Zocor (simvastatin): label change - new restrictions, contraindications, and dose limitations. Posted: June 8, 2011. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Meridia (sibutramine

2014 eMedicine Pediatrics

203. Polycystic Ovarian Syndrome (Diagnosis)

injury. Posted: March 1, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: statin drugs - drug safety communication: class labeling change. Posted: February 28, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Zocor (simvastatin): label change - new restrictions, contraindications, and dose limitations. Posted: June 8, 2011. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Meridia (sibutramine

2014 eMedicine Pediatrics

204. Obesity (Diagnosis)

, Waitzman NJ. A multivariate analysis of federally mandated school wellness policies on adolescent obesity. J Adolesc Health . 2011 Oct. 49(4):363-70. . Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev . 2011 Dec 7. 12:CD001871. . Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics . 2007 Jul (...) . 120(1):e147-57. . Berkowitz R, Fujioka K, Daniels S, et al. Effects of sibutramine treatment in obese adolescents. A randomized trial. Ann Intern Med . July 2006. 145:81-90. . Abbott Laboratories agrees to withdraw its obesity drug Meridia. FDA, U.S. Food and Drug Administration. Available at . Accessed: October 8, 2010. Dunican KC, Desilets AR, Montalbano JK. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother . 2007 Sep. 41(9):1445-55. . Bray GA, Ryan DH. Drug treatment

2014 eMedicine Pediatrics

205. Obesity (Follow-up)

Activity Oude et al concluded that, although no one treatment program can be conclusively recommended, combined behavioral lifestyle interventions produce a significant reduction in weight. Although orlistat and sibutramine (withdrawn from US market) may be used as adjuncts to lifestyle interventions, they must be carefully considered. [ ] Smoking tobacco reduces appetite and is used by many adults and some teenagers to prevent or limit weight gain. The deleterious consequences of smoking clearly (...) . . Coffield JE, Metos JM, Utz RL, Waitzman NJ. A multivariate analysis of federally mandated school wellness policies on adolescent obesity. J Adolesc Health . 2011 Oct. 49(4):363-70. . Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev . 2011 Dec 7. 12:CD001871. . Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled

2014 eMedicine Pediatrics

206. Efficacy and Safety of Alogliptin and Metformin Fixed-dose Combination in Patients With Type 2 Diabetes

inhibitor and/or metformin or related compounds. Has used oral or systemically injected glucocorticoids (including intra-articular injection) or has used weight-loss drugs within 2 months prior to Screening. (Inhaled or topical corticosteroids were allowed.) History of alcohol or substance abuse within 2 years prior to Screening. Has used medicine for weight loss within 60 days prior to Screening (such as Xenical, Sibutramine, Phenylpropanolamine or similar nonprescription drugs). History of organ

2013 Clinical Trials

207. the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes

disease , GI disease, Hepatobilliary diseases, hematological disorders, hypo- or hyperthyroidism, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones, Smokers Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2013 Clinical Trials

208. The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Trial

) and to have maintained a stable body weight for the previous 3 months. Exclusion Criteria: any co-morbid conditions that would make participation in a walking program medically inadvisable. subjects currently participating in a diet or lifestyle intervention for weight loss or who are on medications known to influence bodyweight or glucoregulation (including antidepressants, sibutramine orlistate, insulin and metformin), will be excluded. If participants are scheduled for any type of surgery that could

2013 Clinical Trials

209. Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

-IV) defined eating disorder Use of, or clinical indication for, one or more of the following medications: lithium, anti-epileptic medication, steroids (oral or inhaled), stimulants, serotonin reuptake inhibitors, mirtazapine, tricyclic antidepressants, thyroid supplementation, sibutramine, metformin, thiazolidinediones, beta-blockers, clonidine, niacin Subjects who have had >10% change in their body weight within the three months prior to enrollment HIV positive subjects Presence of mental

2013 Clinical Trials

210. Targeting Inflammation to Treat Cardiovascular Aging

.) are not included in this study because we are studying healthy middle-aged/older adults. Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study. Hemoglobin <12 mg/dl for men; < 10 mg/dl for women History of alcohol abuse or >10 alcoholic units per week (1 unit= 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 oz alcohol) Low platelets (<100,000 cu mm) On weight loss drugs (e.g., Xenical (orlistat), Meridia (sibutramine

2013 Clinical Trials

211. Vascular Dysfunction in Human Obesity Hypertension

), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications) within 3 months of screening Any surgery within 30 days of screening Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01983462 Contacts Layout table

2013 Clinical Trials

212. Desvenlafaxine Monotherapy in Dysthymia

Disorder, provided that Dysthymic Disorder is currently the diagnosis). Meet DSM-IV criteria for a current episode of major depression within two months prior to screening or who have received treatment for a major depressive episode within six months prior to screening. Substance abuse or dependence including alcohol, within 6 months prior to screening. Patients on the following prohibited treatments: Psychotropics such as other SSRIs, other SNRIs, lithium, sibutramine, tramadol, St. John's Wort

2013 Clinical Trials

213. Inflammation Inhibition in Prediabetic Humans

are studying healthy middle-aged/older adults. Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study. Hemoglobin <12 mg/dl for men; < 10 mg/dl for women History of alcohol abuse or >10 alcoholic units per week (1 unit= 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 oz alcohol) Low platelets (<100,000 cu mm) On weight loss drugs (e.g., Xenical (orilistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine

2013 Clinical Trials

214. Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis

/intervention 4)Hepatic cirrhosis with Child-Pugh score of B or C, and/or concomitant HCC 5)Recent(within 6 months) or concomitant use of agents known to cause hepatic steatosis 7)Recent(within 6 months)change in dose/regimen or first treatment with vitamin E, C, betaine, s-adenosylmethionine, ursodeoxycholate, sylimarin, fibrate, statin, pentoxyfilline, angiotensin II inhibitors, orlistat, sibutramine 8)Ongoing or recent therapy (within 6 months) with vitamin D or with medications known to affect vitamin

2013 Clinical Trials

215. Exercise Resistance in Type 2 Diabetes

, cardiac, liver, lung, or neurological disease that in the opinion of the Investigator would compromise participant safety (A) Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc (A) Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures. (A) New onset (<3 months on a stable regime) hormone replacement therapy. (A) Alcohol

2013 Clinical Trials

216. Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)

, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures New onset (<3 months on a stable regime) use of oral contraceptives or hormone replacement therapy Alcohol or other drug abuse Smoking within the past 3 months Females that are currently or have been pregnant or are currently or have nursed a child within the last 12 months (minimum). Parental enrollment into the study

2013 Clinical Trials

217. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Full Text available with Trip Pro

Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. To assess the association of hypoglycemic treatment regimens with cardiovascular adverse events and mortality in a large population of type 2 diabetic patients at increased cardiovascular risk.This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized (...) to lifestyle intervention with or without sibutramine for up to 6 years. Patients were grouped according to hypoglycemic treatment at baseline. The primary end point was the time from randomization to the first occurrence of a primary outcome event (POE), nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death. Multivariable Cox proportional hazards regression models were used to assess the impact of antiglycemic treatment on POE and all-cause

2013 Diabetes Care Controlled trial quality: uncertain

218. Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients. (Abstract)

overweight/obese cardiovascular high-risk patients from the Sibutramine Cardiovascular OUTcomes trial were studied. Patients were stratified after baseline hemoglobin level and followed for the risks of primary event (comprising nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death) and all-cause mortality. Risk estimates (hazard ratios (HR) with 95% confidence intervals (CI)) were calculated using Cox regression models.Anemia was unadjusted associated

2013 International Journal of Obesity Controlled trial quality: uncertain

219. Antiobesity Effect of Codonopsis lanceolata in High-Calorie/High-Fat-Diet-Induced Obese Rats. Full Text available with Trip Pro

, p.o.), HFD, HFD + wCL (100, 300, or 900 mg/kg/day, p.o.), HFD + cCL (100, 300, or 900 mg/kg/day, p.o.), and HFD + sibutramine. The body weight gains of the administered HFD + CL (wCL or CCL) were lower than those of the rats fed with only the HFD group. Moreover, the weight of adipose pads and the serum levels of triglycerides, total cholesterol, and low density lipoprotein cholesterol in the group administered HDL + CL were significantly lower than in the HFD group. The inhibitory effect of lipid

2013 Evidence-based Complementary and Alternative Medicine (eCAM)

220. Pharmacological interventions for weight loss: a review of the clinical and cost-effectiveness

database. Citation Mujoomdar M, Spry C. Pharmacological interventions for weight loss: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions Overall, all of the included studies that assessed the clinical effectiveness of either orlistat or sibutramine demonstrated that both drugs were capable of promoting weight loss. These two studies concluded that sibutramine was more effective than orlistat. With respect (...) to adverse events, reporting was inconsistent throughout studies, but typically orlistat was associated with gastrointestinal disturbances and several reports suggested that sibutramine might increase blood pressure and heart rate. Indeed adverse reactions have been reported to Health Canada in patients with a history of cardiovascular disease, those with unstable or uncontrolled hypertension, and other contraindicated conditions. Two studies reported that treatment with either orlistat or sibutramine

2009 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>